KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Current Deferred Revenue (2016 - 2023)

Historic Current Deferred Revenue for Jazz Pharmaceuticals (JAZZ) over the last 15 years, with Q3 2023 value amounting to $4000.0.

  • Jazz Pharmaceuticals' Current Deferred Revenue fell 9959.47% to $4000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $4000.0, marking a year-over-year decrease of 9959.47%. This contributed to the annual value of $463000.0 for FY2022, which is 8188.58% down from last year.
  • As of Q3 2023, Jazz Pharmaceuticals' Current Deferred Revenue stood at $4000.0, which was down 9959.47% from $4000.0 recorded in Q2 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Current Deferred Revenue peaked at $13.1 million during Q1 2019, and registered a low of $4000.0 during Q1 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' median Current Deferred Revenue value was $4.0 million (recorded in 2021), while the average stood at $4.8 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Current Deferred Revenue soared by 8806.08% in 2019, and later plummeted by 9980.32% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $9.6 million in 2019, then tumbled by 49.26% to $4.9 million in 2020, then plummeted by 47.42% to $2.6 million in 2021, then plummeted by 81.89% to $463000.0 in 2022, then tumbled by 99.14% to $4000.0 in 2023.
  • Its Current Deferred Revenue stands at $4000.0 for Q3 2023, versus $4000.0 for Q2 2023 and $4000.0 for Q1 2023.